Research Article

The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series

Table 2

Characteristics on fostamatinib.

PatientPlatelets at fostamatinib start (×109/L)Platelet response (platelets ≥ 30 × 109/L)Time to platelet response (days)Peak platelet count (×109/L)Most recent platelet count (×109/L)Rescue therapy on fostamatinibAdverse eventsRemains on fostamatinib at most recent assessmentDiedFostamatinib exposure (days)

120Yes18114074NoNoYesNo252
219Yes010275NoTransaminitisYesNo214
30No811160DexPetechial rash, mild transaminitisNoYes175
4193Yes0193126NoNoYesNo152
527Yes59418Dex and IVIGPetechial rashNoNo216
625Yes19162162NoNoYesNo188
731Yes4614137NoNoYesNo93

Dex, dexamethasone; IVIG, intravenous immunoglobulin.